Home » Topics » BioWorld Science

BioWorld Science
RSS

Capricor initiates phase II HOPE-2 trial of CAP-1002 in Duchenne muscular dystrophy

May 2, 2018

FDA clears Pluristem's IND application for PLX-R18 to treat acute radiation syndrome

May 2, 2018

Exicure reports phase I data on AST-005 in plaque psoriasis

May 2, 2018

Aptevo submits IND for phase I study of APVO-436 in AML and MDS

May 2, 2018

Roche reflects on accomplishments of first quarter 2018

May 2, 2018

DCB discovers type III TKIs for cancer

May 2, 2018

AbbVie presents BRD4 inhibitors

May 2, 2018

FDA grants priority review to sBLA for Keytruda

May 2, 2018

Actelion seeks FDA approval of Opsumit for inoperable chronic thromboembolic pulmonary hypertension

May 2, 2018

FDA approves Tafinlar + Mekinist for adjuvant treatment of BRAF V600-mutant melanoma

May 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.